Doximity (NYSE:DOCS) Stock: Insider Timothy Cabral Sells 10,721 Shares

Doximity, Inc. (NYSE:DOCS) Director Timothy Cabral sold 10,721 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $375,235.00. Following the transaction, the director owned 8,084 shares of the company’s stock, valued at $282,940. The trade was a 57.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Doximity Trading Down 1.3%

Doximity stock opened at $32.45 on Wednesday. The company has a market cap of $5.78 billion, a P/E ratio of 45.07, a price-to-earnings-growth ratio of 34.25 and a beta of 1.29. Doximity, Inc. has a 1-year low of $17.15 and a 1-year high of $54.04. The company has a fifty day simple moving average of $29.33 and a 200 day simple moving average of $25.43.

Doximity (NYSE:DOCS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.17. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The company had revenue of $174.54 million during the quarter. During the same quarter in the prior year, the company earned $0.45 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, equities research analysts forecast that Doximity, Inc. will post 0.74 EPS for the current year.

Analyst Ratings Changes

DOCS has been the topic of a number of recent analyst reports. Wells Fargo & Company lowered Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price on the stock. in a report on Monday, August 10th. Royal Bank Of Canada raised their price target on Doximity from $28.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Barclays lifted their price objective on shares of Doximity from $20.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Friday, August 21st. Weiss Ratings upgraded shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, October 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Doximity from $26.00 to $31.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Doximity has an average rating of “Hold” and a consensus price target of $30.45.

Institutional Trading of Doximity

Several hedge funds have recently added to or reduced their stakes in DOCS. Mirae Asset Global Investments Co. Ltd. acquired a new position in Doximity in the 3rd quarter valued at $45,000. Versant Capital Management Inc increased its position in Doximity by 1,176.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock worth $52,000 after buying an additional 1,683 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Doximity by 59.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock worth $53,000 after buying an additional 695 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Doximity by 79.8% during the third quarter. Bessemer Group Inc. now owns 1,910 shares of the company’s stock worth $54,000 after buying an additional 848 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Doximity by 111.0% in the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after acquiring an additional 1,347 shares during the period. 87.19% of the stock is owned by institutional investors and hedge funds.

Doximity News Summary

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.